anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting over 300,000 people worldwide. It is characterized by the progressive decline of the nervous system that leads to the weakening of muscles which impacts physical function. Approximately, 15% of individuals diagnosed with ALS have a known genetic variant that contributes to their disease. As therapies that slow or prevent symptoms continue to develop, such as antisense oligonucleotides, it is important to discover novel genes that could be targets for treatment. Additionally, as cohorts continue to grow, performing analyses in ALS subtypes, such as primary lateral sclerosis (PLS), becomes possible due to an increase in power. These analyses could highlight novel pathways in disease manifestation.
METHODS: Building on our previous discoveries using rare variant association analyses, we conducted rare variant burden testing on a substantially larger multi-ethnic cohort of 6,970 ALS patients, 166 PLS patients, and 22,524 controls. We used intolerant domain percentiles based on sub-region Residual Variation Intolerance Score (subRVIS) that have been described previously in conjunction with gene based collapsing approaches to conduct burden testing to identify genes that associate with ALS and PLS.
RESULTS: A gene based collapsing model showed significant associations with SOD1, TARDBP, and TBK1 (OR = 19.18, p = 3.67 × 10-39; OR = 4.73, p = 2 × 10-10; OR = 2.3, p = 7.49 × 10-9, respectively). These genes have been previously associated with ALS. Additionally, a significant novel control enriched gene, ALKBH3 (p = 4.88 × 10-7), was protective for ALS in this model. An intolerant domain-based collapsing model showed a significant improvement in identifying regions in TARDBP that associated with ALS (OR = 10.08, p = 3.62 × 10-16). Our PLS protein truncating variant collapsing analysis demonstrated significant case enrichment in ANTXR2 (p = 8.38 × 10-6).
CONCLUSIONS: In a large multi-ethnic cohort of 6,970 ALS patients, collapsing analyses validated known ALS genes and identified a novel potentially protective gene, ALKBH3. A first-ever analysis in 166 patients with PLS found a candidate association with loss-of-function mutations in ANTXR2.
A cosmetic process comprises applying cosmetic composition(s) on contact with keratin material under conditions for dissolution of polymer. The cosmetic composition(s) comprises water-soluble polymer(s), and compound(s) approved for food use made of layer(s) with matrix based on water-soluble polymer. Provided that when composition is formed from single layer with hydroxy propyl methylcellulose as sole water-soluble polymer, the composition eliminates glycerol with disodium salt of fuschin or with mixture of titanium dioxide and brown iron oxide. A cosmetic process for making up and/or caring for keratin material(s), comprises applying cosmetic composition(s) on contact with a keratin material under conditions for dissolution of the polymer. The cosmetic composition(s) comprises water-soluble polymer(s), and compound(s) approved for food use (>=50 wt. %). The water-soluble polymer(s) is in the form of an anhydrous film. The compound(s) approved for food use is made of layer(s) containing a matrix based on water-soluble polymer. Provided that when the composition is formed from a single layer containing hydroxy propyl methylcellulose as sole water-soluble polymer, the composition does not also contain glycerol (28.5 wt.%) in combination with disodium salt of fuschin (28.5 wt.%), or glycerol (21 wt.%) in combination with mixture of titanium dioxide and brown iron oxide (7 wt.%). An independent claim is also included for cosmetic composition for making up and/or caring for the lips in the form of an anhydrous film; the cosmetic composition comprising compound(s) approved for food use (>=50), particle(s) with a color and/or optical effect.
A composition comprising oleanolic acid and the salts and solvates thereof; and one or more compounds selected from the group consisting of ellagic acid, adenine, betaine, choline, miquelianin, p-coumaric acid, pipecolic acid, protocatechuic acid and tyramine, and the salts, prodrugs and solvates thereof. The composition may have a mole ratio of 1:x of oleanolic acid to a compound selected from the group, where x is in the range of 0.1 to 20. Also claimed is a skin care product comprising the composition; selected from skin/hand lotion, cream ointment, paste, skin toner, shaving gel/cream, sunscreen, deodorant, antiperspirant, suntan lotion, after-sun, aftershave, body oil, bath oil, bubble bath. Also claimed is a hair care product comprising the composition; selected from conditioner, detangling lotion, styling gel/cream/wax/lotion, mousse, spray gel, hair tonic spritz, pomade. Also claimed is a cosmetic method for decreasing lipid production in the skin of an individual, comprising contacting the skin with the composition; and a method for decreasing lipid production in sebocytes. The composition may be for use in a method of treatment, of treating a skin disease or disorder associated with over-production of lipids in the skin, which may be selected from acne vulgaris and rosacea.
OBJECTIVE: Chordomas are rare tumors of the skull base and spine believed to arise from the vestiges of the embryonic notochord. These tumors are locally aggressive and frequently recur following resection and adjuvant radiotherapy. Proton therapy has been introduced as a tissue-sparing option because of the higher level of precision that proton-beam techniques offer compared with traditional photon radiotherapy. This study aimed to compare recurrence in patients with chordomas receiving proton versus photon radiotherapy following resection by applying tree-based machine learning models.
METHODS: The clinical records of all patients treated with resection followed by adjuvant proton or photon radiotherapy for chordoma at Mayo Clinic were reviewed. Patient demographics, type of surgery and radiotherapy, tumor recurrence, and other variables were extracted. Decision tree classifiers were trained and tested to predict long-term recurrence based on unseen data using an 80/20 split.
RESULTS: Fifty-three patients with a mean ± SD age of 55.2 ± 13.4 years receiving surgery and adjuvant proton or photon therapy to treat chordoma were identified; most patients were male. Gross-total resection was achieved in 54.7% of cases. Proton therapy was the most common adjuvant radiotherapy (84.9%), followed by conventional or external-beam radiation therapy (9.4%) and stereotactic radiosurgery (5.7%). Patients receiving proton therapy exhibited a 40% likelihood of having recurrence, significantly lower than the 88% likelihood observed in those treated with nonproton therapy. This was confirmed on logistic regression analysis adjusted for extent of tumor resection and tumor location, which revealed that proton adjuvant radiotherapy was associated with a decreased risk of recurrence (OR 0.1, 95% CI 0.01-0.71; p = 0.047) compared with photon therapy. The decision tree algorithm predicted recurrence with an accuracy of 90% (95% CI 55.5%-99.8%), with the lowest risk of recurrence observed in patients receiving gross-total resection with adjuvant proton therapy (23%).
CONCLUSIONS: Following resection, adjuvant proton therapy was associated with a lower risk of chordoma recurrence compared with photon therapy. The described machine learning models were able to predict tumor progression based on the extent of tumor resection and adjuvant radiotherapy modality used.
PURPOSE: To obtain a plaster having elasticity to come into close contact with the uneven surface of the human skin, exhibiting good tacky adhesiveness and feeling in use, peelable without giving pain to the skin and having little tendency to cause low-temperature scald in the case of thermotherapy by forming a tacky adhesive layer having a specific constitution on a substrate. CONSTITUTION: This plaster is composed of a substrate and a tacky adhesive layer made of a foamed tacky adhesive containing a hot-melt polymeric substance (e.g. styrene-butadiene-styrene block copolymer) and formed on the substrate at a thickness of preferably 80-1,000μm. The tacky adhesive is preferably composed of 10-30 pts.wt. of a hot-melt polymeric substance, 10-50 pts.wt. of an alicyclic petroleum resin as a tackifying agent, 15-45 pts.wt. of a softening agent and 1-8 pts.wt. of a water-absorbing polymer. The foaming of the tacky adhesive is preferably carried out by a physical foaming method comprising the mechanical mixing of a gas such as air under heating to uniformly disperse the gas and the foaming of the adhesive under atmospheric pressure.
Initial clinical evidence suggests that the omega-3 fatty acids EPA (eicosapentaenoic acid) and/or DHA (docosahexaenoic acid) may play a therapeutic role in the management of mood disorders. EPA is an essential fatty acid, which can be metabolized to DHA and is a component of the human diet if fish is consumed. Aripiprazole is a novel second general antipsychotic that seems to function as a partial agonist at the dopamine D2 and serotonin 5-HT 1A receptors as well as an antagonist at the serotonin 5-HT 2A receptor. Since it has a favorable adverse event profile in adults, it is an attractive choice for the treatment of youth with bipolar disorder if proven efficacious. Although pilot research showed that omega-3 fatty acids monotherapy treatment resulted in improvement of manic symptoms, the improvement is less dramatic than that observed in trials of antipsychotics. We will test the safety and efficacy of omega-3 fatty acids versus placebo as an adjunctive treatment to open-label aripiprazole in children and adolescents with bipolar disorder.

The proposed study includes 1) the use of a 12-week design to document the response rate 2) careful assessment of safety and tolerability
The present invention relates to a complex between interferon-.beta. and polyethylene glycol, which has high biological activity, and to a method for producing the complex at high efficiency. Namely, the present invention relates to a method for producing an interferon-.beta.  complex comprising binding interferon-.beta. to polyethylene glycol in the presence of at least one additive selected from the group consisting of oligosaccharides having 5 or less sugar units, monosaccharides, their corresponding sugar alcohols, and C2-6 polyhydric alcohols, and to an interferon-.beta. complex produced by the method, which has polyethylene glycol specifically bound with lysine located at the 19th or 134th position in the amino acid sequence of interferon-.beta..
The 308-nm excimer laser (EL) has been widely used for localized vitiligo. Recently, the 311-nm Ti:Sapphire laser (TSL) was developed to treat patients with vitiligo. To compare the efficacy of TSL vs. EL in the treatment of vitiligo.

A randomized controlled non-inferiority trial based on split-body was planned. The paired symmetric vitiliginous lesions will be randomized to either TSL or EL treatment groups. All lesions will be treated twice weekly for a total of 12-week period. The degree of repigmentation will be assessed as % from baseline by using a computer program every 4 weeks, and the non-inferiority margin was set at 10%. Overall 16 patients will be enrolled.
Dystonia is an uncommon brain disorder in which there is abnormal muscle tone producing twisting, writhing movements and abnormal postures. It is associated with abnormal electrical activity in two groups of nerve cells in the brain called the globus pallidus internus (GPi) and the subthalamic nucleus (STN). Deep brain stimulation (DBS) has been shown to be an effective treatment in patients with medically refractory dystonia and is currently approved for both the GPi and STN targets under a humanitarian device exemption (HDE) for use in segmental and generalized primary dystonia as well as focal cervical dystonia. GPi DBS appears to be effective for medication-refractory focal and segmental dystonia affecting the cranial and cervical regions in open-label series, but recently GPi stimulation has been associated with subtle motor disturbances in previously non-dystonic body regions (i.e., arms and legs) in this population of patients. DBS of the STN has also been reported to be effective for treating generalized and cervical dystonia in small open label trials. STN DBS for cranial and cervical regions may provide similar efficacy in the treatment of dystonia as GPi DBS, but without unwanted stimulation-induced motor effects. Objectives of this study are to evaluate the safety and efficacy of STN DBS for dystonia. Up to twenty-five patients will be screened, consented, and enrolled in this study. All patients will undergo bilateral STN DBS for dystonia. Participants will be evaluated pre- and postoperatively with standard dystonia rating scale Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), and a patient questionnaire will be administered postoperatively to determine if patients are experiencing stimulation-induced motor adverse effects and will be logged for safety monitoring. This pilot study will provide preliminary open label efficacy outcomes for STN DBS in the treatment of primary dystonia and will help determine if this target should be compared to GPi DBS in a larger double-blind trial.
PURPOSE: To obtain a skin external agent highly improved in the stability of the α-tocopheryl retinoate, formulated with an α-tocopheryl retinoate and additive(s) selected from acidic amino acids, salts thereof, basic amino acids and salts thereof. CONSTITUTION: This skin external agent contains pref. 0.001-10 (esp. 0.01-2.0) wt.% of an α-tocopheryl retinoate known as an effective ingredient for preventing or treating keratosis etc., and preventing or remedying skin aging and 0.001-10wt.% of at least one kind of additive selected from acidic amino acids, salts thereof, basic amino acids and salts thereof. The α-tocopheryl retinoate is pref. the ester of DL-α-tocopherol and all-trans-retinoic acid. The acidic amino acid is e.g. aspartic acid, glutamic acid, and basic amino acid is e.g. arginine, lysine, hydroxylysine.
Malaria is a major health problem in the Solomon Islands, with an annual estimated incidence of 158 per 1000 population in 2005, and P. falciparum and P. vivax responsible for respectively 71% and 29% of the clinical cases. Not much is known about the burden of malaria in pregnancy and the effectiveness of weekly chloroquine prophylaxis, the national policy for the prevention of malaria in pregnancy. In Honiara, the capital, 42.7% of the pregnant women are anaemic at their first antenatal clinic (ANC) visit. In a national data-base, clinical malaria in pregnancy was associated with an increased risk of anaemia. High levels of chloroquine drug resistance have been reported (67% treatment failure at day 28 in 2001). Among women who attended an ANC in Honiara and had been offered chloroquine prophylaxis, a high low birth weight risk among primigravidae compared to multigravidae was noted. This information indicates that the current policy may not be optimal for the prevention of malaria and its effects in pregnancy. Intermittent preventive treatment (IPTp) with sulfadoxine-pyrimethamine (SP) in pregnancy is an alternative strategy which has been introduced in many malarious countries in sub-Saharan Africa. Studies which compared IPTp with chloroquine prophylaxis in Africa showed that IPTp was more beneficial. Resistance to SP monotherapy in the Solomon islands has not been examined; however, the resistance to the combination of SP and chloroquine is low (\< 10%). IPTp with SP has so far not been implemented in a region where P. vivax is common, and the effect of SP on P. vivax is not clear.

We propose a randomized controlled trial to assess the effectiveness of IPTp with SP compared to chloroquine prophylaxis in Honiara, the Solomon Islands. As outcome measures we will examine the effect on anaemia in third trimester, placental malaria, maternal anaemia at the time of delivery, infant birth weight, and prematurity. Outcomes in women allocated IPTp with SP will be compared with those allocated chloroquine prophylaxis. We expect 2504 women from Honiara City Council to participate in the randomised controlled trial. To assess the burden of malaria in pregnancy in other locations women we expect 1000 women to participate in a survey at the time of delivery among women not participating in the trial. At the end of this study, we will know the burden of malaria in pregnancy in Honiara and Guadalcanal, and we will be able to assist in developing evidence based national guidelines for malaria prevention among pregnant women in the Solomon Islands. The information obtained will be important for other areas and countries with a similar epidemiology of malaria in pregnancy.
Blood tests for follow-up and treatment are widely used in intensive care units (ICU). Although its etiology is very diverse, phlebotomy performed due to frequent laboratory tests is among the preventable causes of anemia. In this observational study, blood tests performed on patients treated in intensive care units followed up in our clinic between 01.April.2023 - 31.May.2023 (2 months) will be examined. Patients' age, presence of additional disease, indication for admission to the unit, Acute Physiology and Chronic Health Assessment II (APACHE II), Sequential Organ Failure Assessment (SOFA) and Glasgow coma scale (GCS), hemoglobin values will be recorded. The daily blood test will record the amount of blood drawn for analysis (in milliliters), where it was taken from (peripheral, central venous or arterial catheter), and the amount of excess blood. Statistical analysis will be performed in terms of patient characteristics, routine blood volumes and development of anemia.
OBJECTIVE: To compare the efficacy of CoolSense and EMLA cream on pain reduction during intravenous cannulation in the pediatric population.
METHODS: A total of 140 American Society of Anesthesiologist I/II children of 6-12 y requiring intravenous cannulation before induction of anesthesia were randomized into two groups of 70 each. Before intravenous cannulation, group I received CoolSense pretreatment while group II received EMLA cream pretreatment. The primary outcome was to assess the efficacy of CoolSense and EMLA cream on pain reduction during intravenous cannulation. The secondary outcomes included the anxiety level of children, successful first attempt at cannulation, technical difficulties faced, adverse reactions, and parents' satisfaction score.
RESULTS: There was a significant reduction in pain scores during intravenous cannulation in the CoolSense group compared to the EMLA cream group (mean pain score 7.14 ± 4.322 versus 29.32 ± 8.95, p value 0.001). Comparison of pre- and postprocedural anxiety levels showed a decrease in the anxiety level in the CoolSense group (p value = 0.003) as compared to the EMLA group. The duration of application of CoolSense was significantly less than EMLA cream.
CONCLUSION: CoolSense was more efficacious in reducing the pain of intravenous cannulation than the EMLA cream. In the pediatric population, CoolSense appears to be a simple and rapid means of providing adequate analgesia for venous cannulation.
Thrombotic diseases impose a significant global health burden, and conventional drug-based thrombolytic therapies are encumbered by the risk of bleeding complications. In this study, we introduce a novel drug-free nanomedicine founded on tea polyphenols nanoparticles (TPNs), which exhibits multifaceted capabilities for localized photothermal thrombolysis. TPNs were synthesized through a one-pot process under mild conditions, deriving from the monomeric epigallocatechin-3-gallate (EGCG). Within this process, indocyanine green (ICG) was effectively encapsulated, exploiting multiple intermolecular interactions between EGCG and ICG. While both TPNs and ICG inherently possessed photothermal potential, their synergy significantly enhanced photothermal conversion and stability. Furthermore, the nanomedicine was functionalized with cRGD for targeted delivery to activated platelets within thrombus sites, eliciting robust thrombolysis upon laser irradiation across diverse thrombus types. Importantly, the nanomedicine's potent free radical scavenging abilities concurrently mitigated vascular inflammation, thus diminishing the risk of disease recurrence. In summary, this highly biocompatible multifunctional nanomaterial holds promise as a comprehensive approach that combines thrombolysis with anti-inflammatory actions, offering precision in thrombosis treatment.
<P>PROBLEM TO BE SOLVED: To clarify the amino acid sequence of human-derived PGIS, and to provide the human-derived PGIS and a DNA encoding the same.  <P>SOLUTION: A DNA containing the DNA having a nucleotide sequence encoding the amino acid sequence of the human-derived prostacyclin synthase (PGIS) substantially depicted in Sequence No.12, a vector containing the DNA and a host cell transformed with the vector are provided. In a method for producing the human-derived PGIS, the host cell is cultured in a medium. A polypeptide having the amino acid sequence of the human-derived PGIS substantially depicted in Sequence No.12 and an antibody showing a reactivity with the human-derived PGIS are also provided. A pharmaceutical composition contains the DNA or the vector containing the DNA. In methods for promoting the production of PGI<SB>2</SB>and for treating diseases induced by decreased PGI<SB>2</SB>production, the DNA or the vector containing the DNA is introduced into a living body.  <P>COPYRIGHT: (C)2006,JPO&NCIPI